康弘药业自研创新药KHN707片获批开展用于失眠症的临床试验

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its self-developed KHN707 tablets for the treatment of insomnia [1] Group 1: Product Development - KHN707 tablets are a selective orexin receptor 2 (OX2R) antagonist and classified as a Class 1 innovative chemical drug [1] - The formulation of KHN707 is in tablet form [1] Group 2: Research Findings - Preliminary research results indicate that KHN707 has good safety and demonstrates effective therapeutic effects in insomnia models [1] - The clinical application prospects for KHN707 are expected to be favorable [1]